Montreal, Canada
Immuni T, founded in 2005 and headquartered in Canada, is a Contract Research Organization (CRO) specializing in biotherapeutics and immunomodulator services. The company operates in the Analytics, Biotechnology, and Pharmaceutical industries, offering competitively priced services in GLP/GCLP regulated laboratories.
They possess notable expertise in customized cell-based assays and bioanalysis, including flow cytometry and ELISA assays. A key innovation is their ex vivo method for assessing the immunogenic potential of new biotherapeutics and biosimilars, a rapid and cost-effective technique leveraging freshly-collected PBMC from multiple donors. This method aids in selecting lower immunogenic leads and comparing biosimilars to originators.
Immuni T's portfolio includes developing and validating immunogenicity methodologies, ligand-binding assays for PK analysis, and various functional assays like cytotoxicity, Treg, and NK assays. Despite a solid market presence, details of recent investments or investors are unavailable.
